Daraxonrasib for advanced bile duct cancer with KRAS mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new pill called Daraxonrasib that targets cancers with a specific KRAS mutation. It is for people with advanced bile duct cancer that has grown after at least one prior treatment, to see if it can shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your bile duct cancer must be advanced (not removable by surgery) or spread to other parts of the body.
- You must have already tried at least one round of chemotherapy or immunotherapy that didn't work or caused too many side effects.
- Your cancer must have a specific mutation called KRAS, which the study drug targets.
- You must be well enough to perform daily activities (ECOG score of 0 or 1).
- You must not have taken certain other cancer drugs that target the RAS pathway before, and you must not have certain heart or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
This study tests a new drug (daraxonrasib) for children with solid tumors that have a RAS mutation and have not responded to standard treatments. The drug targets the mutated RAS protein to slow or stop cancer growth.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests an experimental drug (SNV1521) combined with a RAS inhibitor for people with advanced pancreatic cancer. The goal is to see if this combination is safe and can help shrink or control the cancer.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.